| Langue d'origine | English |
|---|---|
| Pages (de-à) | 670-673 |
| Nombre de pages | 4 |
| Journal | American Journal of Respiratory and Critical Care Medicine |
| Volume | 197 |
| Numéro de publication | 5 |
| DOI | |
| Statut de publication | Published - mars 1 2018 |
Note bibliographique
Funding Information:Supported by the Universities of Padova and Ferrara, the Italian Ministry of University and Research, and the Italian Society of Pediatric Respiratory Diseases.
Funding Information:
The Canadian Cohort Obstructive Lung Disease (CanCOLD) study is currently funded by the Canadian Respiratory Research Network (CRRN) and industry partners AstraZeneca Canada Ltd., Boehringer Ingelheim Canada Ltd., GlaxoSmithKline Canada Ltd., and Novartis. Researchers at the Research Institute of the McGill University Health Centre (Montreal, PQ, Canada) and the University of British Columbia Centre for Heart Lung Innovation (Vancouver, BC, Canada) lead the project. Previous funding partners are the Canadian Institutes of Health Research (CIHR/Rx&D Collaborative Research Program Operating Grant 93326); the Respiratory Health Network of the FRSQ; and industry partners Almirall, Merck Nycomed, Pfizer Canada Ltd., and Theratechnologies. The funders had no role in the study design, data collection and analysis, or preparation of the manuscript.
Funding Information:
The Canadian Cohort Obstructive Lung Disease (CanCOLD) study is currently funded by the Canadian Respiratory Research Network (CRRN) and industry partners AstraZeneca Canada Ltd., Boehringer Ingelheim Canada Ltd., GlaxoSmithKline Canada Ltd., and Novartis. Researchers at the Research Institute of the McGill University Health Centre (Montreal, PQ, Canada) and the University of British Columbia Centre for Heart Lung Innovation (Vancouver, BC, Canada) lead the project. Previous funding partners are the Canadian Institutes of Health Research (CIHR/Rx&D Collaborative Research Program Operating Grant 93326); the Respiratory Health Network of the FRSQ; and industry partners Almirall, Merck Nycomed, Pfizer Canada Ltd., and Theratechnologies. The funders had no role in the study design, data collection and analysis, or preparation of the manuscript. The authors thank the men and women who participated in the study. The authors also acknowledge the contributions of the following colleagues in the CanCOLD Collaborative Research Group who could not be listed as authors, owing to the author limit in a research letter: Liyun Zheng and Dr. D. E. O’Donnell (Queen’s University, Kingston, ON, Canada); Dr. Kenneth R. Chapman (University of Toronto, Toronto, ON, Canada); and Dr. Jeremy Road and Dr. James C. Hogg (UBC James Hogg Research Center, Vancouver, BC, Canada).
ASJC Scopus Subject Areas
- Pulmonary and Respiratory Medicine
- Critical Care and Intensive Care Medicine